Rezafungin for Treatment of Chronic Pulmonary Aspergillosis (CPA) in Adults with Limited Treatment Options
- Conditions
- Chronic Pulmonary Aspergillosis
- Interventions
- First Posted Date
- 2025-01-27
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Mundipharma Research Limited
- Target Recruit Count
- 60
- Registration Number
- NCT06794554
Rezafungin for Treatment of Pneumocystis Pneumonia in HIV Adults
- Conditions
- Pneumocystis Pneumonia
- Interventions
- Drug: Co-Trimoxazole
- First Posted Date
- 2023-04-28
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Mundipharma Research Limited
- Target Recruit Count
- 50
- Registration Number
- NCT05835479
- Locations
- 🇿🇦
University of Cape Town, Cape Town, South Africa
🇿🇦Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa
🇿🇦Helen Joseph Hospital, Johannesburg, South Africa
Rezafungin Paediatric PK Study in Paediatric Subjects From Birth to <18 Years of Age
- First Posted Date
- 2022-09-09
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- Mundipharma Research Limited
- Target Recruit Count
- 32
- Registration Number
- NCT05534529
- Locations
- 🇩🇪
Universitätsklinikum Essen Zentrum für Kinder- und Jugendmedizin, Essen, Germany
🇩🇪Universitätsklinikum Frankfurt, Goethe Universität Klinik für Kinder- und Jugendmedizin, Frankfurt, Germany
🇩🇪Universitätsklinikum Münster Klinik für Kinder- und Jugendmedizin, Münster, Germany
Study of Tinostamustine for Adjuvant Treatment of Glioblastoma
- Conditions
- Glioblastoma Multiforme
- Interventions
- First Posted Date
- 2022-06-27
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Mundipharma Research Limited
- Target Recruit Count
- 12
- Registration Number
- NCT05432375
- Locations
- 🇪🇸
Hospital Universitario Vall d'Hebron, Barcelona, Spain, Barcelona, Spain
🇪🇸Hospital Universitario Ramón y Cajal, Madrid, Spain, Madrid, Spain
🇪🇸South Texas Accelerated Research Therapeutics (START), Madrid, Spain
Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation
- Conditions
- PneumocystisInvasive Fungal DiseaseProphylaxis of Invasive Fungal InfectionsMycosesFungal InfectionFungemiaMold InfectionAspergillusCandidemiaInvasive Candidiasis
- Interventions
- Drug: Intravenous PlaceboDrug: Trimethoprim-sulfamethoxazole (TMP/SMX)Drug: Oral Placebo
- First Posted Date
- 2020-04-30
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Mundipharma Research Limited
- Target Recruit Count
- 600
- Registration Number
- NCT04368559
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
🇺🇸University of Minnesota Physicians, Minneapolis, Minnesota, United States
🇺🇸Mary Hitchcock Memorial Hospital Dartmouth-Hitchcock, Lebanon, New Hampshire, United States
Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.
- Conditions
- Small Cell Lung CancerSoft Tissue SarcomaTriple-negative Breast CancerOvarian CancerEndometrial Cancer
- Interventions
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Mundipharma Research Limited
- Target Recruit Count
- 71
- Registration Number
- NCT03345485
- Locations
- 🇺🇸
New York University, New York, New York, United States
🇨🇦Juravinski Cancer Centre, Hamilton, Ontario, ON, Canada
🇨🇦BC Cancer-Vancouver, Vancouver, Vancouver, BC, Canada
Study to Assess Pharmacokinetic (PK), Bioavailability & Food Effect of MR902 Compared With Immediate Release (IR) Morphine Sulphate Oral Solution
- Conditions
- Opioid Substitution Treatment
- Interventions
- First Posted Date
- 2016-05-16
- Last Posted Date
- 2016-05-16
- Lead Sponsor
- Mundipharma Research Limited
- Target Recruit Count
- 84
- Registration Number
- NCT02773316
A Study to Evaluate the Effect of Fluticasone/Formoterol Breath Actuated Inhaler (BAI) or Relvar® Ellipta® DPI on Ventilation Heterogeneity in Asthma
- Conditions
- Asthma
- Interventions
- Drug: Fluticasone/Vilanterol DPI (Relvar Ellipta DPI)Drug: Fluticasone/Formoterol BAI
- First Posted Date
- 2016-04-28
- Last Posted Date
- 2018-10-23
- Lead Sponsor
- Mundipharma Research Limited
- Target Recruit Count
- 105
- Registration Number
- NCT02753712
- Locations
- 🇦🇺
Allergy immunology and Respiratory medicine, The Alfred Hospital, Melbourne, Victoria, Australia
🇦🇺Epworth Eastern Medical Centre, Box Hill, Victoria, Australia
🇳🇿Otago Respiratory Research Unit, Dunedin, New Zealand
A Study to Compare Fluticasone /Formoterol Breath Actuated Inhaler (BAI) and Ultibro in Subjects With Fixed Airflow Obstruction and Elevated Eosinophils
- Conditions
- ACOS (Fixed Airflow Obstruction and Elevated Eosinophils)
- Interventions
- First Posted Date
- 2016-02-29
- Last Posted Date
- 2016-12-12
- Lead Sponsor
- Mundipharma Research Limited
- Target Recruit Count
- 2
- Registration Number
- NCT02693769
- Locations
- 🇸🇰
JURMED, s.r.o., Košice, Slovakia
Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies
- Conditions
- Hematological MalignanciesMultiple MyelomaHodgkin's LymphomaCutaneous T Cell Lymphoma
- Interventions
- First Posted Date
- 2015-10-15
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Mundipharma Research Limited
- Target Recruit Count
- 106
- Registration Number
- NCT02576496
- Locations
- 🇺🇸
Mayo Clinic, Phoenix, Arizona, United States
🇺🇸Columbia University Medical Center, New York, New York, United States
🇺🇸University Hospitals Cleveland Seidman Cancer Center, Cleveland, Ohio, United States